Abstract
Introduction
The ability of the immune system to control malignant tumors has long been the subject of study, and cancer immunotherapy, such as using immune checkpoint blockers, is now recognized as one of the most promising therapeutic strategies (1, 2) . Mycobacterium bovis Bacille Calmette-Guérin (BCG) is well appreciated as a substantial activator of the immune system (3, 4) . The mycobacterial cell wall comprises a vast array of proteins, lipids and lipoglycans, including lipoarabinomannan (LAM) and its related biosynthetic precursor lipomannan (LM), which influence the host immune system (5-7). We and others have demonstrated the immunomodulation capacity of LAM and LM both in vitro and in vivo (8, 9) . BCG has also been assessed for its therapeutic efficacy against various cancers in clinical trials (10) (11) (12) , and intravesical instillation of BCG is now widely applied for the treatment of superficial bladder cancer as an effective immune adjuvant (13) . However, the precise cellular mechanisms underlying the anti-tumor efficacy of BCG are unclear.
Eosinophils express a variety of surface molecules such as chemokine receptors, cytokine receptors, immunoglobulin receptors and Toll-like pattern recognition receptors (14) . Eosinophils play key roles in host defense against parasites; however, they are also involved in the pathophysiology of various allergic disorders. Regarding immunotherapy for cancer, the cytotoxic potential of eosinophils against tumor cells has been reported in both experimental and clinical settings (2, 15, 16) . Eosinophils, which possess a specific arsenal of cytotoxic molecules, have been detected in the peri-tumoral infiltrate of various cancers (17) . Consistent with this observation, tumor-associated tissue eosinophilia reveals the correlation of a prognosis in various cancers including head and neck cancer, bladder cancer and prostate cancer (15, 18, 19) . Thus, increasing evidence indicates an important role for eosinophils in the anti-tumor response.
Adoptive transfer of T cells has potential utility as immunotherapy for cancer, as subsets of T cells can directly kill tumor cells and also indirectly activate other immune cells, such as granulocytes (2, (20) (21) (22) (23) (24) . Memory T cells survive for long periods in the body of the host and provide antigen-specific protection against neo-antigens expressed on various tumors (25) (26) (27) . T h 2 cell-mediated anti-tumor immune responses are largely dependent on the production of T h 2 cytokines such as IL-4, IL-5 and IL-13, accompanied by the recruitment of polymorphonuclear cells, such as neutrophils and eosinophils (2, (20) (21) (22) (23) (24) . Notably, T h 2 cell therapy is reported to be effective against a CTL-resistant tumor model (24) . We also revealed the existence of a cellular network in which IL-4 from activated memory T h 2 cells induces potent and long-lasting antitumor effects in vivo through the activation of NK cells (28) .
Here, we investigated the mechanisms underlying BCG-LM-and memory T h 2-mediated anti-tumor immunity via the accumulation of eosinophils in the tumor microenvironment. BCG-LM stimulation induced the production of superoxide in eosinophils. BCG-LM-stimulated dendritic cells (DCs) showed increased production of C-C motif ligand (CCL) 5/ Rantes, which recruits eosinophils into the tumor microenvironment. BCG-LM and memory T h 2 cells exerted a synergistic effect on tumor progression by cooperatively enhancing the eosinophil function and facilitating their accumulation in tumor sites. Thus, BCG-LM together with memory T h 2 cells may have potent therapeutic potential for cancer immunotherapy.
Methods

Ethics statement
Animal care was conducted in accordance with the guidelines of Chiba University. All animal experiments were approved by the Chiba University Review Board for Animal Care (number 28-182).
Mice and cell lines
Female BALB/c mice (6-8 weeks) were purchased from CLEA Inc. (Tokyo, Japan). Gata1 tm6Sho mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Anti-ovalbumin (OVA)-specific TCR-αβ (DO11.10) transgenic (Tg) mice were provided by Dr Dennis Loh (Washington University, St. Louis) (29) . A20-OVA cell line was kindly provided by Dr M. J. Bevan (30) and cultured with RPMI-1640 medium supplemented with 10% FCS and Geneticin. A20 parental cells were maintained in RPMI-1640 medium supplemented with 10% FCS. EL4 cells, C57BL/6 T lymphoma and EG7 cells, an OVAtransfected clone of EL4, were purchased from American Type Culture Collection (Manassas, VA, USA).
Preparation for BCG-CW, BCG-LAM and BCG-LM
BCG cell wall (BCG-CW), BCG-LAM and BCG-LM were purified as previously described (8) and dissolved in saline for both in vivo and in vitro experiments.
Mass spectrometric analysis of lipoglycans, LAM and LM
For the determination of high-molecular-weight lipoglycans (LAM/LM), we introduced MALDI TOF mass spectrometric analysis using a Voyager DE-STR MALDI TOF mass spectrometer (Applied Biosystem) with a pulse laser emitting at 337 nm. The samples were analyzed in the reflectron mode with an accelerating voltage operating in the negative ion mode of 25 kV. As the matrix, 2,5-dihydroxy benzoic acid was used at a concentration of 10 mg ml −1 , in a mixture with water. A total of 1.0 µl of lipoglycan, at a concentration of 10 mg ml −1 , was mixed with 1.0 µl of the matrix solution. The sample mixture was applied onto the sample plate as a 1.0 ml droplet. The samples were then allowed to crystalized at room temperature.
Fatty acid composition and carbohydrate structure analysis of lipoglycans (LAM/LM)
Fatty acid compositions of lipoglycans, BCG-LAM/LM and phosphatidylinositol mannosides (PIMs) were analyzed as methylesters on gas chromatography or gas chromatography-mass spectrometry. For the analysis of carbohydrate structure of lipoglycans LAM/LM, partially methylated alditol acetate derivatives were prepared and the terminal mannose, 2,6-mannose, 6-mannose and 2-mannose and also 5-arabinofuranose and 3,5-arabinofuranose were determined.
Generation of effector T h 2 cells and memory T h 2 mice
Effector T h 2 cells were generated as previously described (31) . The effector T h 2 cells (2-3 × 10 7 cells) were transferred intravenously into BALB/c recipient mice on day 0. At 4-5 weeks after cell transfer, these mice were used as memory T h 2 mice.
Immune therapy model of cancer
A20-OVA or A20 cells (6 × 10 6 cells) were intradermally injected into BALB/c mice with or without BCG-CW, BCG-LAM or BCG-LM (100 µg) on day 0. BCG-CW, BCG-LAM or BCG-LM (100 µg) or BCG-CW-, BCG-LAM-or BCG-LMpulsed bone marrow-derived DCs (BMDCs; 2 × 10 5 cells) were injected into the tumor site on days 2 and 4 (20, 21) . The size of each tumor was assessed using micro-calipers. The tumor volume was calculated using the following formula, as described previously (32) . In some experiments, A20-OVA cells (6 × 10 6 cells) were injected intradermally into BALB/c mice on day 0. On days 7 or 9, the mice were administered BCG-LM and OVA (100 µg) intratumorally together with the intravenous injection of memory T h 2 cells (1 × 10 7 or 2 × 10 7 cells).
Isolation of splenocytes and tumor-infiltrating leukocytes
Splenocytes and lymph node cells were passed through a nylon mesh and centrifuged, and then the red blood cells were lysed. Tumors were minced and treated with collagenase (20 U ml 
Isolation of mouse BMDCs and bone marrow-derived eosinophils
BMDCs were generated as previously described (33) and purified by positive selection and magnetic separation with anti-CD11c magnetic beads (Miltenyi Biotec). Bone marrowderived eosinophils (BMEOs) were cultured at 10 6 ml −1 in medium containing 100 ng ml −1 stem cell factor (SCF) (R&D Systems) and 100 ng ml −1 FLT3 ligand (R&D Systems) from days 0 to 4. On day 4, the medium containing SCF and FLT3-L was replaced with medium containing 10 ng ml −1 recombinant mouse (rm) IL-5 (R&D Systems).
ELISA
BMDCs were plated at 5 × 10 6 cells per well with or without BCG-CW, BCG-LAM or BCG-LM (1-100 µg ml −1 ). The supernatants were collected after 24-48 h of activation and stored at −80°C. The protein levels of CCL5, CCL24 and IL-6 were measured using ELISA kits (R&D Systems Inc., or BD Biosciences, San Jose, CA, USA) in accordance with the manufacturer's instructions.
Quantitative PCR analysis
Total RNA was isolated from tumor samples (three mice in each day) using the TRIzol reagent (Sigma-Aldrich). Reverse transcription was carried out with Superscript II RT (Invitrogen, Carlsbad, CA, USA). Samples were subjected to a real-time PCR analysis on an ABI PRISM 7300 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) under standard conditions. TaqMan probes (Roche) and gene specific primers were used for detection, and expression values normalized by the hypoxanthine-guanine phosphoribosyltransferase (HPRT). Specific primers, and Roche Universal Probes used in quantitative reverse transcriptase PCR for mouse genes were as follows: Hprt: 5′-TCCTCCTCAGACCGCTTTT-3′ (forward), 5′-CCTGGTTCATCATCGCTAATC-3′ (reverse), probe #95; Ccl2: 5′-CATCCACGTGTTGGCTCA-3′ (forward), 5′-GATCATCTTGCTGGTGAATGAGT-3′ (reverse), probe #62; Ccl5: 5′-TGCAGAGGACTCTGAGACAGC-3′ (forward), 5′-GAGTGGTGTCCGAGCCATA-3′ (reverse), probe #110; Ccl17: 5′-TGCTTCTGGGGACTTTTCTG-3′ (forward), 5′-GAATGGCCCCTTTGAAGTAA-3′ (reverse), probe #27; Ccl22: 5′-TCTTGCTGTGGCAATTCAGA-3′ (forward), 5′-GAGGGTGACGGATGTAGTCC-3′ (reverse), probe #84; Cxcl1: 5′-GACTCCAGCCACACTCCAAC-3′ (forward), 5′-TGACAGCGCAGCTCATTG-3′ (reverse), probe #83.
Histological analysis and immunofluorescent staining
Tumors were injected into the skin of mice and collected in 2-9 days. Sections of tumors were fixed in buffered 10% formalin and stained with hematoxylin and eosin. Immunofluorescent staining was performed as previously described (34) . Anti-Siglec-F (E50-2440)-PE, anti-CD4 (RM4-5)-FITC, anti-KJ-1-PE (BD Pharmingen, San Diego, CA, USA), and 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen) were used. Data sets were analyzed using the Imaris software program (Bitplane, Zurich, Switzerland).
Total reactive oxygen species/superoxide production
Superoxide production from eosinophils was determined using a total reactive oxygen species (ROS)/superoxide detection kit (Enzo Life Sciences, Plymouth Meeting, PA, USA) in accordance with the manufacturer's instructions.
Detection of apoptosis
BMEOs were cultured with or without BCG-CW, BCG-LAM or BCG-LM (100 µg) for 24 h. The eosinophil-mediated cytotoxicity against PKH26 (Sigma-Aldrich)-labeled A20-OVA was measured in complete medium at 3.0-5.0 × 10 4 targets per well in V-bottom plates containing BCG-CW, BCG-LAM or BCG-LM-pulsed eosinophils (E:T ratio of 100). Cell apoptosis was measured by staining of Annexin V-450, B220-APCCy7 (BD Pharmingen) and propidium iodide.
RNA sequencing
Total cellular RNA was extracted with TRIzol reagent (Invitrogen). For cDNA library construction, the TruSeq RNA Sample Prep Kit v2 (Illumina, San Diego, CA, USA) was used in accordance with the manufacturer's protocol. Sequencing the library fragments was performed on a HiSeq 1500 System (Illumina). For the data analysis, read sequences (61 bp) were aligned to the mm10 mouse reference genome [University of California, Santa Cruz (UCSC), December 2011] using Bowtie (version 0.12.8) and TopHat (version 1.3.2). Fragments per kilobase of exon per million mapped reads for each gene were calculated using Cufflinks (version 2.0.2).
Statistical analyses
Data were analyzed using the Graphpad Prism software program version 6 (GraphPad Software, Inc., La Jolla, CA, USA). The significance between two groups was determined using a two-tailed Student's t-test. Differences in the survival were analyzed using the log-rank test. Differences with *P values <0.05 or 0.01 were considered significant.
Results
BCG-LM inhibited tumor growth, accompanied by massive infiltration of eosinophils into the tumor microenvironment
The administration of BCG is known to induce anti-tumor immunity against various tumors, including bladder cancer (35) . However, precise cellular mechanisms by which BCG induces anti-tumor immunity have been poorly understood. The BCG cell envelope consists of diverse lipophilic components such as LM, LAM, lipopeptides and PIMs (8) . The experimental procedures to obtain BCG-LAM/LM from Mycobacterium bovis BCG Tokyo172 were based on successive detergent extraction and phenol phase separation and led us to get a good recovery of the BCG-LAM/LM, with minimum contamination of nucleic acid, protein and lipid and free materials. BCG-LAM and LM fractions were fully separated and collected by gel filtration chromatography and the purity of each component was assessed by SDS-PAGE. On MALDI/TOF mass spectrometry, we have tried to detect the molecular weight of BCG-LAM and LM from Mycobacterium bovis BCG Tokyo. LM showed clear [M-H+2Na] ions ranging from 2000 to 8400 Da, corresponding to 12-49 mannose residues, centering at 26, 28, 34 mannoses dominating even mannose residues and with three acyl groups (Supplementary Figure S1A , available at International Immunology Online). Further, the deacylated BCG-LM after mild alkali hydrolysis of BCG-LM showed essentially the same types of mass pattern on TOF-Mass spectra, due to the loss of fatty acyl groups (Supplementary Figure S1B, available at International Immunology Online, lower panel versus upper panel). In order to clarify the branching structure of sugar chain of BCG-LAM/LM, partial methylated alditol astate derivative was prepared and gas chromatography-mass spectrometry analysis was carried out. In BCG-LM, t-Manp was 36.6%, 2,6-Manp was 37.6%, 6-Manp was 18.6% and To determine potential mechanisms by which BCG inhibits the growth of cancer cells, we decided to directly administer the BCG-CW, BCG-LAM or BCG-LM to A20-OVA tumors that had been intradermally injected into BALB/c mice (Supplementary Figure S1D , available at International Immunology Online). The administration of BCG-LAM and BCG-CW mildly and poorly inhibited tumor growth, respectively, resulting in a poor survival (Fig. 1A and B) . In sharp contrast, local tumor growth was completely inhibited by the administration of BCG-LM, and the mice treated with BCG-LM showed significantly prolonged survival compared to other mice (*P < 0.05; Fig. 1A and B) . In addition to A20 cells (a B-cell-originated tumor), the tumor growth of T-cell-originated tumors such as EL4 cells and EG7 cells was also suppressed by the administration of BCG-LM but not by the administration of BCG-LAM or BCG-CW (Fig. 1C) . BCG-LM treatment also resulted in prolonged survival of mice injected with T-celloriginated tumors (Fig. 1D) . A histological analysis revealed the massive infiltration of eosinophils into the tumor microenvironment, even at an early time point (day 2) after the administration of BCG-LM (Fig. 1E, left panel) , that continued for at least 7 days (day 9) (Fig. 1E, second from the left to right panels). However, the administration of BCG-LAM or BCG-CW showed no obvious infiltration of eosinophils (Supplementary Figure S1E , available at International Immunology Online). A FACS analysis confirmed that the administration of BCG-LM induced the accumulation of eosinophils in local tumor invasion sites (Fig. 1F) . The administration of BCG-LM exerted small effects on the infiltration of eosinophils in the spleen (Supplementary Figure S1F , available at International Immunology Online). An immunohistological analysis of the tumors from mice that had been administered BCG-LM intratumorally revealed the infiltration of Siglec-F + cells within the tumor (Fig. 1G) . Taken together, these findings show that the direct administration of BCG-LM into the tumor mass resulted in potent anti-tumor effects accompanied by the massive infiltration of eosinophils into the local tumor invasion sites without a systemic increase in the numbers of eosinophils.
BCG-LM enhanced the cytotoxic activity in eosinophils through the increased production of superoxide
Given the accumulation of eosinophils in the tumor microenvironment induced by the intratumoral administration of BCG-LM (Fig. 1E-G) , we next sought to determine the direct contribution of BCG-LM to the cytotoxic activity in eosinophils. To this end, we differentiated freshly isolated murine bone marrow progenitors into eosinophils (herein referred to as BMEOs) and performed a cytotoxic assay using BM-derived eosinophils with or without BCG-LM (Supplementary Figure  S2A -C, available at International Immunology Online). Co-cultivation with BCG-LM increased the cytotoxicity of eosinophils (E/T ratio: 27.6-71.5%) compared to controls (E/T ratio: 13.0-35.4%) ( Fig. 2A , left panel versus the secondfrom-right panel; Supplementary Figure S2D , available at International Immunology Online). In contrast, co-cultivation of BCG-LAM or BCG-CW showed small effects on the cytotoxicity of eosinophils ( Fig. 2A; Supplementary Figure S2D , available at International Immunology Online).
ROS, including superoxide, are key inflammatory mediators produced by eosinophils (14) . We hypothesized that the induction of ROS may be a potential mechanism through which BCG-LM enhances the cytotoxicity of eosinophils. Indeed, the treatment of pyocyanin, a pharmacological inducer of superoxide, enhanced the cytotoxicity of eosinophils and increased the production of superoxide ( Fig. 2A,  right panel; Fig. 2B , right panel; Supplementary Figure S2E , available at International Immunology Online). BCG-LM induced the production of superoxide from eosinophils, but neither BCG-CW nor BCG-LAM induced such production at all (Fig. 2B) . To confirm the importance of eosinophils in the inhibition of tumor growth in vivo, we injected A20 tumor cells intradermally into mice that genetically lacked eosinophils (Gata1 tm6Sho mice) (14) . Adoptive transfer of BM-derived eosinophils into Gata1 tm6Sho mice resulted in the significant inhibition of tumor growth (*P < 0.05) with prolonged survival (*P < 0.05; Fig. 2C ). Thus, BCG-LM stimulation enhanced the cytotoxicity of eosinophils and resulted in the direct induction of superoxide in eosinophils.
BCG-LM induced the accumulation of eosinophils in local tumor sites via the induction of CCL5 from BMDCs
BCG-LM activates DCs and induces effector functions (8).
We wished to clarify whether or not BCG-LM modulated the function of DCs that may also contribute to the inhibition of tumor growth. To address this point, we primed BMDCs with BCG-LM for 4 h, washed the cells to remove BCG-LM and then transferred them into an A20-OVA tumor mass that had been generated by intradermal injection into BALB/c mice (Supplementary Figure S3A , available at International Immunology Online). The administration of BCG-LM-pulsed BMDCs significantly inhibited tumor growth (*P < 0.05; Fig. 3A) ; intratumorally, the mice injected with BCG-LMpulsed BMDCs showed significant prolonged survival (***P < 0.0001; Fig. 3B ).
To determine the potential molecular mechanisms by which BCG-LM-pulsed BMDCs induced anti-tumor immunity in vivo, we conducted a genome-wide gene expression analysis of BCG-LM-pulsed BMDCs using RNA sequencing (Fig. 3C) . A total of 474 genes showed greater than 4-fold change between BCG-LM-pulsed BMDCs and untreated BMDCs, including 269 up-regulated and 205 down-regulated entries for BCG LM-pulsed BMDCs (Supplementary Figure  S3B , available at International Immunology Online). Among the cytokine-and chemokine-related genes, the expression of 17 genes was up-regulated on stimulation of BMDCs with BCG-LM (Fig. 3C ). Among these cytokine-and chemokinerelated genes, the expression of Ccl5, which is crucial for the recruitment of eosinophils to local inflammatory sites, was 11.8 times higher in BCG-LM pulsed DCs than in control DCs (Fig. 3C, arrow) . BCG-LM treatment, but not BCG-LAM treatment, resulted in dose-dependently increased protein expression of CCL5 in BMDCs in vitro (Fig. 3D) . The administration of BCG-LM along with anti-CCL5-neutralizing antibody ameliorated the inhibition of tumor growth induced by BCG-LM in vivo (Fig. 3E) . Consistent with this result, the accumulation of eosinophils in the tumor microenvironment was decreased by the addition of anti-CCL5-neutralizing antibody (55.8 versus 31.4%) (Fig. 3F) . Taken together, these findings suggest that BCG-LM-induced CCL5 from DCs may play an important role in the accumulation of eosinophils in the tumor microenvironment and their anti-tumor activity in vivo.
BCG-LM enhanced memory T h 2 cell-induced anti-tumor activity
The accumulation of eosinophils at local inflammation sites is known to be mediated by the type 2 immune response, especially by T h 2 cells (14) . We and others have reported that memory T h 2 cells induce potent anti-tumor immunity (23, 28) . The Ccl5 expression at local tumor invasion sites was increased in mice with memory T h 2 cells in a time-dependent manner (Fig. 4A, gray bars) . Furthermore, the administration of BCG-LM enhanced the induction of Ccl5 expression at local tumor invasion sites in mice with memory T h 2 cells (Fig.  4A, black bars) . The administration of BCG-LM in mice with memory T h 2 cells enhanced the accumulation of eosinophils (62.5 versus 91.3%) at local tumor invasion sites (Fig. 4B ). An immunohistological analysis of the tumors of mice with adoptively transferred memory T h 2 cells revealed the enhanced infiltration of Siglec-F + cells within the tumor (Fig.  4C) . Stimulation of BMDCs by BCG-LM also resulted in the induction of Ccl2, Ccl17, Ccl22 and Cxcl1, which are known to be involved in the migration of memory T h 2 cells to local inflammatory sites (36) (Fig. 4D) . Consistent with these results, a FACS analysis and an immunohistological analysis showed that the administration of BCG-LM resulted in enhanced accumulation of memory T h 2 cells (0.8 versus 11.0%) at local tumor invasion sites (Fig. 4E and F) . Furthermore, cocultivation with memory T h 2 cells increased the cytotoxicity of eosinophils (E/T ratio: 27.6-56.1%) (Supplementary Figure S4A , available at International Immunology Online, top panels). The enhancement of cytotoxicity of eosinophils by memory T h 2 cells was ameliorated by neutralizing IL-4 or IL-5 (Supplementary Figure S4A , available at International Immunology Online, middle and bottom panels).
To explore the contribution of memory T h 2 cells to BCG-LM in cancer immunotherapy, we administered BCG-LM and performed adoptive transfer of memory T h 2 cells in mice in which A20-OVA tumor cells had been transplanted 10 days prior (Fig. 4G) . Tumor growth was completely inhibited by the administration of BCG-LM with adoptive transfer of memory T h 2 cells (Fig. 4H) . Even a single administration of BCG-LM together with adoptive transfer of memory T h 2 cells resulted in an anti-tumor effect (Supplementary Figure  S4B and C, available at International Immunology Online). Taken together, these findings suggest that the administration BCG-LM and adoptive transfer of memory T h 2 cells may have potent therapeutic potential as immunotherapy in cancer patients.
Discussion
We highlighted the critical role of BCG-LM in anti-tumor responses induced by eosinophils and memory T h 2 cells within the tumor microenvironment. BCG-LM directly regulated the cytotoxic activity of eosinophils through the upregulation of superoxide. BCG-LM stimulation also resulted in the increased production by BMDCs of CCL5, which recruits eosinophils to local inflammatory sites. Furthermore, BCG-LM acted as an adjuvant enhancing the anti-tumor effects of memory T h 2 cells, which are potent inducers of eosinophils. Thus, our findings provide the cellular basis for a novel approach through which BCG-LM works as a potential adjuvant for cancer immunotherapy (see Fig. 5 ).
The mycobacterial cell wall comprises various kind of proteins, lipids and lipoglycans, including LAM and LM, which are known to modulate the host immune system (5, 6, 9). The anti-tumor effects of BCG via macrophages and DCs have been well elucidated (37) . However, the precise mechanism underlying the anti-tumor activity induced by BCG remains unclear. We found that BCG-LM but not BCG-LAM is crucial for the induction of anti-tumor activity in our system, both in vivo and in vitro. One of the potential mechanisms underlying the different anti-tumor activity between BCG-LM and BCG-LAM is that only BCG-LAM includes a substantial level of the mannose-capped form of LAM (ManLAM) (38, 39) . ManLAM is known to inhibit LPS-induced IL-12 production by DCs (40) and mycobacteria-or LPS-induced DC maturation (41, 42) . ManLAM also suppresses the TLR2-dependent activation of eosinophils (1) . Thus, ManLAM may negatively regulate the anti-tumor activity of DCs and eosinophils.
Tumor-associated tissue eosinophilia is often observed in the tumor microenvironment (15) . Eosinophilia is known to be a favorable prognostic factor in bladder cancer, although the association between tumor-associated tissue eosinophilia and the clinical outcome of other types of cancers has been controversial (15) . In our experimental setting, the administration of BCG-LM promoted substantial infiltration of eosinophils into the tumor microenvironment, suggesting that eosinophils are involved in the anti-tumor activity of BCG-LM. This notion is further supported by evidence that BCG-LM stimulates DCs to produce Ccl5, a major eosinophil chemoattractant. Consistent with this, eosinophils dominantly express Ccr3, which is a receptor for Ccl5 (43) . We also found that BCG-LM directly enhanced the cytocidal activity of eosinophils against cancer cells and that superoxide is released from eosinophils by BCG-LM stimulation, while BCG-LAM or BCG-CW showed no effect on the activation of eosinophils. ROS are produced in cells through the metabolism of oxygen and can function as destructive molecules in high concentrations (44) . Superoxide may produce hydroxyl radicals via hydrogen peroxide and promote lipid peroxidation of tumor cells, which causes tumor cell death.
We and others previously reported the anti-tumor potential of T h 2 cells (28, 45) . In this study, we demonstrated that tumor-specific memory T h 2 cells can enhance the recruitment of eosinophils to the tumor microenvironment and the anti-tumor effect caused by BCG-LM. Recently, the indirect effect of eosinophils in anti-tumor T-cell responses has been reported (16) . Hammerling et al. showed that tumor-associated tissue eosinophils promote vascular normalization and secrete chemoattractants that cause the infiltration of tumorspecific CTLs, thereby eradicating tumor cells (16) . Thus, tumor-specific memory T h 2 cells, which can recruit eosinophils to the tumor microenvironment, are involved in multiple pathways for cancer elimination and may therefore be a key factor for cancer immunotherapies, including BCG therapy. In summary, our findings suggest that BCG-LM may be a novel adjuvant for immune therapy against cancer. Considering the recent successes of immunotherapy, BCG-LM may hold promise as a novel anti-tumor reagent in combination of other anti-tumor antibodies, including anti-PD-1, anti-PDL1 and anti-CTLA4 antibodies.
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